[go: up one dir, main page]

MX2012001513A - Uso de melanocortinas para tratar la dislipidemia. - Google Patents

Uso de melanocortinas para tratar la dislipidemia.

Info

Publication number
MX2012001513A
MX2012001513A MX2012001513A MX2012001513A MX2012001513A MX 2012001513 A MX2012001513 A MX 2012001513A MX 2012001513 A MX2012001513 A MX 2012001513A MX 2012001513 A MX2012001513 A MX 2012001513A MX 2012001513 A MX2012001513 A MX 2012001513A
Authority
MX
Mexico
Prior art keywords
melanocortins
treat dyslipidemia
dyslipidemia
alcoholic
treat
Prior art date
Application number
MX2012001513A
Other languages
English (en)
Inventor
Michael Dewitt Culler
Heather A Halem
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of MX2012001513A publication Critical patent/MX2012001513A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con ligandos de péptidos de receptores de melanocortina, en particular el receptor de melanocortina 4, y como tales, son útiles en el tratamiento de la dislipidemia y complicaciones asociadas tales como hígado graso alcohólico y no alcohólico.
MX2012001513A 2009-08-05 2010-07-30 Uso de melanocortinas para tratar la dislipidemia. MX2012001513A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27348809P 2009-08-05 2009-08-05
PCT/US2010/043832 WO2011017209A1 (en) 2009-08-05 2010-07-30 Use of melanocortins to treat dyslipidemia

Publications (1)

Publication Number Publication Date
MX2012001513A true MX2012001513A (es) 2012-05-22

Family

ID=43544604

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001513A MX2012001513A (es) 2009-08-05 2010-07-30 Uso de melanocortinas para tratar la dislipidemia.

Country Status (12)

Country Link
US (2) US20120135923A1 (es)
EP (1) EP2461681A4 (es)
JP (1) JP2013501053A (es)
KR (1) KR20120059520A (es)
CN (1) CN102548399A (es)
AU (1) AU2010279719A1 (es)
BR (1) BR112012002445A2 (es)
CA (1) CA2769883A1 (es)
IN (1) IN2012DN01493A (es)
MX (1) MX2012001513A (es)
RU (1) RU2012108110A (es)
WO (1) WO2011017209A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103316345B (zh) 2007-11-05 2016-05-18 益普生制药股份有限公司 黑皮质素治疗胰岛素敏感的应用
US20120226018A1 (en) * 2009-11-16 2012-09-06 Ipsen Pharma, S.A.S. Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
KR102038677B1 (ko) 2011-06-14 2019-10-30 입센 파마 에스.에이.에스 활성 성분으로 멜라노코르틴 수용체 리간드를 함유하는 지속-방출형 조성물
ES2732077T3 (es) 2011-12-29 2019-11-20 Rhythm Pharmaceuticals Inc Método para tratar trastornos asociados con el receptor de melanocortina-4 en portadores heterocigotos
CN118240012A (zh) * 2013-03-15 2024-06-25 节奏制药公司 肽组合物
EP2970389B1 (en) 2013-03-15 2020-08-19 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
ES2985734T3 (es) 2015-09-30 2024-11-07 Rhythm Pharmaceuticals Inc Método de tratamiento de trastornos asociados a la vía del receptor de la melanocortina-4
US20210221867A1 (en) * 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1635813A4 (en) * 2003-06-06 2009-07-01 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
US20080306008A1 (en) * 2004-11-04 2008-12-11 Nova Nordisk A/S Peptides for Use in the Treatment of Obesity
EP2548568B1 (en) * 2005-07-08 2018-01-10 Ipsen Pharma Melanocortin receptor ligands
RU2401841C2 (ru) * 2005-07-08 2010-10-20 Ипсен Фарма С.А.С. Лиганды рецепторов меланокортинов
TWI364290B (en) * 2007-05-25 2012-05-21 Ipsen Pharma Sas Melanocortin receptor ligands modifled with hydantoin
TW200848424A (en) * 2007-06-15 2008-12-16 Sod Conseils Rech Applic Cyclic peptide melanocortin receptor ligands
CN103316345B (zh) * 2007-11-05 2016-05-18 益普生制药股份有限公司 黑皮质素治疗胰岛素敏感的应用

Also Published As

Publication number Publication date
JP2013501053A (ja) 2013-01-10
CN102548399A (zh) 2012-07-04
RU2012108110A (ru) 2013-09-10
US20130331324A1 (en) 2013-12-12
CA2769883A1 (en) 2011-02-10
EP2461681A1 (en) 2012-06-13
US20120135923A1 (en) 2012-05-31
AU2010279719A1 (en) 2012-03-01
BR112012002445A2 (pt) 2015-10-13
WO2011017209A1 (en) 2011-02-10
KR20120059520A (ko) 2012-06-08
EP2461681A4 (en) 2013-04-24
IN2012DN01493A (es) 2015-06-05

Similar Documents

Publication Publication Date Title
MX2012001513A (es) Uso de melanocortinas para tratar la dislipidemia.
SG178602A1 (en) Dual variable domain immunoglobulins and uses thereof
PH12012500774A1 (en) Dual variable domain immunoglobulins and uses thereof
PH12012500815A1 (en) Dual variable domain immunoglobulins and uses thereof
MX2012004415A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2012001262A (es) Inmunoglobulinas de dominio variable doble y usos de las misma.
MX2011011669A (es) Inmunoglobulinas de dominio variable dual y usos de las misma.
MX2011011670A (es) Inmunoglobulinas de dominio variable dual y usos de las mismas.
NZ595939A (en) Use of modified peptide gamma-glu-abu for imparting or enhancing food or beverage taste
EP2373692A4 (en) IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE
WO2008015383A3 (en) Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies
MX2010003013A (es) Inhibicion de angiogenesis.
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
MX2010007867A (es) Composiciones de limpieza personal concentradas.
MX2010008696A (es) Composiciones de proteina estabilizadas.
PH12012502523A1 (en) Dual variable domain immunoglobulins and uses thereof
MA32372B1 (fr) INHIBITEURS DPP-IV à UTILISER DANS LE TRAITEMENT DE LA NAFLD
IN2012DN02081A (es)
EP2068798A4 (en) METHODS, COMPOSITIONS AND APPARATUSES FOR TREATING INJURIES USING ALTERED PRESSURES FROM ATMOSPHERIC PRESSURES
WO2009049284A3 (en) Compositions and methods for improved glycoprotein sialylation
MX2012001306A (es) Inhibicion de matastasis de tumor.
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
WO2012006341A3 (en) Anti-ron antibodies
WO2010097788A3 (en) Visfatin therapeutic agents for the treatment of acne and other conditions
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF

Legal Events

Date Code Title Description
FA Abandonment or withdrawal